Table 1.
Characteristics of Statin Non-Adherence Predictors Studies
| Source | Country | Sample Size |
Adherence Measure: PDC, Discontinuation, Both, Self Report |
Predictors | Maximum follow-up duration |
% Adherent |
|---|---|---|---|---|---|---|
| Ellis et al. (2004)30 | US | 4802 | Both | Age, Gender, Race, MI, Visits, Lipid Testing, Costs | 3 years |
a 3 years: 62.2% PP; a 3 years: 61.2% SP |
| Benner et al. (2004)22 | US | 19422 | PDC | Age, Gender, Income, Depression, MI, HTN, DM, Regimen Complexity, Visits. Lipid Testing | 2 years | 3 months: 51% 6 months: 36% 1 year: 30% 2 years: 27% 3 years: 25% |
| Donnelly et al. (2008)27 | UK | 6462 | PDC | Age, Gender, MI, HTN, DM | 13 years | 3 months: 94% 1 year: 66% 5 years: 75% 10 years: 68% |
| Howell et al. (2001)32 | UK | 1010 | PDC | Age, Gender, MI, HTN, DM, Lipid Testing | 12 years | 12 years: 75% |
| Caspard et al. (2005)23 | US | 4776 | Both | Age, Gender | 5 years | 6 months: 80% 1 years: 74% 2 years:65% 3 years:61% |
| Benner et al. (2002)9 | US | 34501 | PDC | Age, Gender, Race, MI, HTN, DM, Regimen Complexity, Visits, Depression | 10 years | 3 months: 79% 6 months: 56% 1 year: 50% 10 years: 42% |
| Avorn et al. (1998)8 | US/Canada | 7287 | PDC | Age, Gender, MI, HTN, DM, Regimen Complexity, Visits, Statin naïve | 1 year | NA |
| Mann et al. (2007)21 | US | 71 | Self-reportc | Age, Race | 6 months | 6 months: 43% |
| Yu et al.33 | US | 19038 | Both | Age, Gender, MI, HTN, DM, Visits | 2.5 years | 6 months: 66% 1 year: 59.3% |
| Perrault et al. (2005)31 | Canada | 17958 | Discontinuation | Age, Gender, Income, HTN, DM, Regimen Complexity, Visits | 3 years |
b 6 months: 65%(PP) b 6 months: 71% (SP) b 3 years: 35% (PP) b 3 years: 45% (SP) |
| Larsen et al. (2002)24 | Denmark | 3623 | Discontinuation | Age, Gender | 5 years | Not reported |
| Chodick a et al. (2008)17 | Israel | 136052 | Discontinuation | Age, Gender, Income, HTN, DM, Visits | 10 years | 3 years: 37% |
| Chodick b et al. (2008)17 | Israel | 93866 | Discontinuation | Age, Gender, Income, HTN, DM, Visits | 10 years | 4 years: 23% |
| Yang et al. (2002)25 | UK | 22408 | Discontinuation | Age, Gender, Regimen Complexity, Visits | 8 years | 1 year: 70% |
| Abraha et al. (2003)26 | Italy | 39222 | Discontinuation | Gender, MI, HTN, DM | 4.5 years | 4.5 years: 13% |
| Hudson et al. (2007)18 | Canada | 34735 | Discontinuation | Age, HTN, DM, Regimen Complexity, Visits | 5 years | 2 years: 78% (M) 2 years: 80% (W) 5 years: 63% (M) 5 years: 68% (W) |
| Schneeweiss et al. (2007)29 | US | 31561 | PDC | Age, Gender, Income, MI, HTN, DM, Visits, Costs | 9 months | 9 months: 56% (Baseline) 51% (After cost increase) |
| Vinker et al. (2008)28 | Israel | 47680 | PDC | Age, Gender, Income | 8 years | 1 year: 39% 3 years: 18% 6 years: 10% |
| Jackevicius et al. (2002)34 | Canada | 22379 | Discontinuation | Age, Gender, MI, HTN, DM, Regimen Complexity, Visits | 2 years | 2 years: 40% ACS 36% CAD 25% PP |
| Rasmussen et al. (2007)19 | Denmark | 30078 | Discontinuation | Income | 6 years | NA |
| Rasmussen et al. (2007)5 | Canada | 17823 | PDC | Age, Gender, Income, HTN, DM, | 4 years | 1 year: 87.5% |
| Eagle et al. (2004)35 | 14 countries, 4 continents: NA, SA, Europe, Australia | 6320 | Discontinuation | HTN, DM | 1 year | 5 mo – 1 year: 13% discontinued statin |
| Hsu et al. (2006)36 | US | 199179 | PDC | Costs | 1 year | NA |
MI – Myocardial infarction or cardiovascular disease (CVD) equivalent
Comorbidities – comorbidities excluding hypertension (HTN), diabetes (DM) and CVD
ACS: acute coronary syndrome; CAD: chronic coronary artery disease; PP: primary prevention; SP: secondary prevention
a
These data reflect PDC only
b
These data reflect PDC only
c
Only included paper to not use pharmacy/claims refill data, used validated Morisky Scale